For the period (end-September 30), the company posted revenue of 3.4 million euros ($3.8 million U.S.), down 15% from 4 million euros ($4.6 million) in the first half of 2017. Net loss for the period was 8.9 million euros ($10.3 million), compared with a net loss of 8.8 million euros ($10.2 million) in 2017.
Going forward, Median plans to focus its research and development efforts on iBiopsy, its artificial intelligence and cloud computing imaging platform. The company has already signed research collaboration agreements for iBiopsy in the areas of lung cancer, prostate cancer, and nonalcoholic steatohepatitis, it said.
Copyright © 2018 AuntMinnieEurope.com